S
Solve Therapeutics
Targeted cancer therapies enhancing safety and precision
About Solve Therapeutics
Solve Therapeutics is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) and precision diagnostics for solid tumors. The company builds targeted cancer therapies designed to improve safety and efficacy by combining highly selective antibodies with its proprietary CloakLink platform, a hydrophilic linker system engineered to deliver payloads more efficiently and reduce off-target toxicity.
Read full description
Its pipeline includes multiple clinical-stage ADCs with differentiated designs, optimized for stability in circulation and controlled drug release within tumor cells. Solve Therapeutics also integrates companion diagnostic tools to enable precise patient selection, an approach that supports more effective treatment decisions and aligns with the industry shift toward personalized oncology.
Backed by major life-science investors, the company advances its programs through a platform that spans early discovery to clinical development, supported by internal expertise in targeted radiochemistry, chemistry-based design, and translational biology. Solve Therapeutics positions itself at the intersection of technology and cancer drug development, aiming to produce best-in-class therapies for hard-to-treat solid tumors.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 89.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
- Technology
- Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2025 | $120M | $480M | Abingworth · Merck & Co. · Ally Bridge Group · Yosemite | ↗ |
| EARLY VCOther financing | Dec 2024 | $50M | $202M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Solve Therapeutics is 370 monthly website visits, down 40.3% over the last three months. Solve Therapeutics's team grew 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CereiusDurham, United StatesInnovative targeted radiotherapeutics enhancing cancer treatment efficacy and safety through precision molecular targeting
→
CereiusLondon, United KingdomPersonalized and Highly Targeted Radiotherapy
$26Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
General Atlantic
Decheng Capital
Matrix Capital Management
Surveyor Capital
Yosemite
Abingworth
Merck & Co.
Ally Bridge Group
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Solve Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Solve Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.